Mecure, a listed provider of innovative health solutions, has declared an 11 percent year-on-year drop in profit after tax to N568.7 million in the first quarter of 2025 from N641.5 million in the same period of 2024, as rising operational costs ate into bottom-line gains.
The firm’s cost of sales rose to N8.99 billion in Q1 2025 from N5.41 billion, leaving gross profit at N4.30 billion, which is up 61 percent year-on-year but still under pressure from input-cost inflation.
Top-line growth remained robust, with revenue climbing 65 percent to N13.29 billion in Q1 2025 from N8.08 billion, driven by higher product volumes and price adjustments amid sustained demand for its flagship pharmaceutical offerings.